Embla Medical hf 将来の成長

CPSE:EMBLA - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,022	106	111	155	5
12/31/2025	939	92	97	137	5
12/31/2024	864	74	24	107	5
9/30/2024	840	69	69	111	N/A
6/30/2024	820	61	54	96	N/A
3/31/2024	804	57	47	93	N/A
12/31/2023	786	58	52	94	N/A
9/30/2023	766	52	43	82	N/A
6/30/2023	750	45	37	72	N/A
3/31/2023	730	43	28	57	N/A
12/31/2022	719	43	35	61	N/A
9/30/2022	715	47	49	76	N/A
6/30/2022	719	57	50	79	N/A
3/31/2022	728	62	69	96	N/A
12/31/2021	719	64	74	101	N/A
9/30/2021	701	50	54	77	N/A
6/30/2021	692	48	63	84	N/A
3/31/2021	637	11	62	82	N/A
12/31/2020	630	6	68	92	N/A
9/30/2020	639	20	65	92	N/A
6/30/2020	635	19	78	109	N/A
3/31/2020	680	59	75	109	N/A
12/31/2019	686	66	63	95	N/A
9/30/2019	675	83	72	102	N/A
6/30/2019	652	85	55	84	N/A
3/31/2019	631	83	47	76	N/A
12/31/2018	613	80	39	69	N/A
9/30/2018	599	69	48	78	N/A
6/30/2018	593	64	N/A	71	N/A
3/31/2018	579	58	N/A	72	N/A
12/31/2017	569	58	N/A	74	N/A
9/30/2017	553	49	N/A	64	N/A
6/30/2017	543	51	N/A	68	N/A
3/31/2017	538	52	N/A	61	N/A
12/31/2016	521	51	N/A	66	N/A
9/30/2016	507	49	N/A	69	N/A
6/30/2016	495	50	N/A	65	N/A
3/31/2016	483	51	N/A	74	N/A
12/31/2015	483	51	N/A	66	N/A
9/30/2015	488	54	N/A	67	N/A
6/30/2015	497	55	N/A	77	N/A
3/31/2015	502	57	N/A	79	N/A
12/31/2014	509	59	N/A	85	N/A
9/30/2014	509	58	N/A	86	N/A
6/30/2014	487	55	N/A	82	N/A
3/31/2014	460	46	N/A	71	N/A
12/31/2013	436	40	N/A	66	N/A

アナリストによる今後の成長予測

収入対貯蓄率: EMBLAの予測収益成長率 (年間16.9% ) は貯蓄率 ( 1.2% ) を上回っています。

収益対市場: EMBLAの収益 ( 16.9% ) はDanish市場 ( 11.6% ) よりも速いペースで成長すると予測されています。

高成長収益: EMBLAの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: EMBLAの収益 ( 8.5% ) Danish市場 ( 10% ) よりも低い成長が予測されています。

高い収益成長: EMBLAの収益 ( 8.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: EMBLAの自己資本利益率は、3年後には低くなると予測されています ( 11.2 %)。

Embla Medical hf 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Össur hf. Provides Earnings Guidance for the Year 2024

Össur hf. Reaffirms Financial Guidance for the Year 2023

Recent updates

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Now 21% undervalued

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

New minor risk - Financial position

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2024

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Össur hf. Reaffirms Financial Guidance for the Year 2023

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings: EPS misses analyst expectations

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Össur hf. Announces Executive Changes

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Consensus EPS estimates fall by 12%

Full year 2022 earnings: Revenues in line with analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2023

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Less than half of directors are independent

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Investor sentiment improved over the past week

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Price target decreased to kr.42.00

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Price target decreased to kr.43.70

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 22% undervalued after recent price drop

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

Now 20% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Össur Launches New POWER KNEE

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report